Home/Reports

What you will find here

Two things live on this page: HealthSignals’ own gated reports, and a running index of the public reports we track ourselves — regulators, industry associations, and health authorities across Latin America and the United States. The index is grouped by the areas we cover and refreshed periodically.

HealthSignals Reports

Our own gated intelligence — proprietary analysis, available on request.

HealthSignals Special Report — Diabetes in Latin America 2026: The Control Gap
Cardio-Metabolic · LatAm

Patients get diagnosed and medicated. Then the system loses them — in the only two markets that measure the whole chain.

Get the report →
More HealthSignals reports coming soon

External Intelligence

Public reports from regulators, industry associations, and health authorities across Latin America and the United States — the sources we track ourselves, grouped by area. Last updated September 2026.

Oncology
State of Cancer Care in America — ASCO · ongoing series. Flagship benchmark on oncology practice, workforce, and access in the US.
ACS Annual Report: Cancer Mortality Rates Decline — American Cancer Society / The ASCO Post · Jan 2025. US cancer mortality trends and the access gaps still limiting progress.
Cardio-Metabolic
2025 Heart Disease and Stroke Statistics — American Heart Association · Jan 2025. US and global data on cardiovascular disease burden and outcomes.
2025 Annual Report — American Diabetes Association · 2025. Program and research priorities shaping US diabetes care this year.
Neuroscience
2025 Alzheimer’s Disease Facts and Figures Report — Alzheimer’s Association · 2025. Prevalence, mortality, and caregiving burden data for the US.
Rare & Genetic Diseases
State Report Card 2024 — NORD · 2024. State-by-state ranking of US rare disease health care coverage and policy.
Infectious Diseases & Vaccines
Immunization in the Americas: 2024 Summary — PAHO/WHO · 2024. Regional vaccination coverage and the children still missing routine doses.
Flu Vaccination Coverage, United States, 2024–25 Season — CDC · 2025. Season-by-season US influenza vaccination uptake by age and state.
Pharma & Market Access
New Innovation Report and 2025 Policy Agenda — PhRMA · 2025. US industry positioning on innovation policy and drug pricing reform.
Industry Analysis Reports — BIO · ongoing series. Biotech investment, M&A, and clinical development trend data.
The Global Use of Medicines 2025: Outlook to 2029 — IQVIA Institute · 2025. Global and regional medicine spending and volume forecasts to 2029.
Patient W.A.I.T. Indicator 2024 — Latin America — FIFARMA / IQVIA · 2024. How long patients in 10 LatAm markets wait for innovative medicines after global launch.
8º Relatório Anual de Pesquisa Clínica — ANVISA (Brazil) · 2025. Clinical research authorized for drug and biologic registration in Brazil.
Informe Programa Demuestra la Calidad de Medicamentos 2024 — INVIMA (Colombia) · 2024. Post-market quality testing results across Colombia’s medicine supply.
Policy & Markets
National Health Expenditure Data — CMS · ongoing series. The official US benchmark for national health spending, by payer and category.
Inflation Reduction Act: Initial Implementation of Medicare Drug Pricing Provisions — GAO · 2025. How CMS is rolling out Medicare drug price negotiation under the IRA.
Public Opinion on Prescription Drugs and Their Prices — KFF · ongoing tracker. Polling on affordability and support for US drug-pricing reform.
Prescription Drug Policy, 2024 and 2025: The Year in Review and the Year Ahead — Health Affairs Forefront · 2025. A policy-by-policy recap of US drug pricing regulation.
La urgencia de invertir en los sistemas de salud en América Latina y el Caribe — CEPAL–OPS · 2024. Special report on health investment gaps and inequality across LatAm.
Informe Anual de la OPS correspondiente al 2024 — PAHO/OPS · 2025. Regional health security and technical cooperation results for the Americas.